- Home
- TCMD vs PBYI Comparison
TCMD vs PBYI Comparison
Compare TCMD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | PBYI |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 263.4M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCMD | PBYI |
|---|---|---|
| Price | $29.21 | $6.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $23.25 | $7.00 |
| AVG Volume (30 Days) | 332.5K | ★ 378.0K |
| Earning Date | 02-17-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.66 | ★ 59.87 |
| EPS | ★ 0.77 | 0.74 |
| Revenue | ★ $311,513,000.00 | $211,995,000.00 |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $38.69 | ★ $8.28 |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $8.61 | $2.58 |
| 52 Week High | $30.24 | $6.22 |
Technical Indicators
Market Signals| Indicator | TCMD | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 69.88 |
| Support Level | $29.02 | $5.81 |
| Resistance Level | $29.92 | $5.73 |
| Average True Range (ATR) | 0.92 | 0.24 |
| MACD | -0.22 | 0.05 |
| Stochastic Oscillator | 60.90 | 87.77 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.